Back to search

Article

Reduction of pain and functional disability over time in patients treated with zavegepant: A Post-hoc analysis of the BHV3500-301 Phase 3 Randomized Controlled Trial

2024-11-11

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>Migraine is a disabling disorder that impacts 40 million people in the US. Zavegepant is the first calcitonin gene-related peptide (CGRP) receptor antagonist nasal-spray approved for the acute treatment of migraine with or without aura in adults. This study aimed to evaluate the proportion of patients in various pain and functional disability states over 48-hour...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b24564cc-9f15-5a04-a4ce-1d67a2443078
DOI
10.21203/rs.3.rs-5167096/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Reduction of pain and functional disability over time in patients treated with zavegepant: A Post-hoc analysis of the BHV3500-301 Phase 3 Randomized Controlled TrialDOI 10.21203/rs.3.rs-5167096/v1
Zavegepant intranasal spray for the Acute Treatment of Migraine : A Systematic Review and Meta-Analysis of Randomized Clinical TrialsSemantic proximity
An Investigation into the Prevalence of Migraine and its Prophylactic Treatment Patterns in the Czech RepublicSemantic proximity
Effectiveness and Tolerability of Anti-Calcitonin Gene-related Peptide Therapy for Migraines and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USASemantic proximity
Real-World experience of interictal burden and treatment in migraine: a qualitative interview studySemantic proximity
Efficacy of fremanezumab in refractory chronic migraine patients: Real-world data from the Hull Migraine Clinic, UKSemantic proximity
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – An updated systematic review and meta-analysisSemantic proximity
Atogepant: Mechanism of action, clinical and translational scienceSemantic proximity
Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world DataSemantic proximity
Unveiling the Efficacy and Safety of Erenumab, a Monoclonal Antibody Targeting Calcitonin Gene-related Peptide (CGRP) Receptor, in Patients with Chronic and Episodic Migraine: A GRADE-assessed Systematic Review and Meta-analysis of Randomized Clinical Trials with Subgroup AnalysisSemantic proximity
Comparative Long-Term Effectiveness Of OnabotulinumtoxinA (Botox) And Anti CGRP In Migraine Prevention: A Systematic ReviewSemantic proximity
Real-world experience of erenumab in patients with chronic or episodic migraine in the UAESemantic proximity
Safety efficacy and tolerability of the calcitonin gene-related peptide monoclonal antibodies for migraine prevention in a real world settingSemantic proximity
Select a neighboring publication to make it the new centre.